vs
ANI PHARMACEUTICALS INC（ANIP）与Ranger Energy Services, Inc.（RNGR）财务数据对比。点击上方公司名可切换其他公司
ANI PHARMACEUTICALS INC的季度营收约是Ranger Energy Services, Inc.的1.7倍（$247.1M vs $142.2M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 2.3%，领先8.9%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs -0.6%），ANI PHARMACEUTICALS INC自由现金流更多（$29.1M vs $17.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 1.9%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Ranger Energy Services是北美领先的陆上油田服务提供商，为上游油气运营商提供完井、修井、钻机作业及产能优化等全套解决方案，业务主要覆盖美国本土的页岩和致密资源开采作业区。
ANIP vs RNGR — 直观对比
营收规模更大
ANIP
是对方的1.7倍
$142.2M
营收增速更快
ANIP
高出30.3%
-0.6%
净利率更高
ANIP
高出8.9%
2.3%
自由现金流更多
ANIP
多$12.0M
$17.1M
两年增速更快
ANIP
近两年复合增速
1.9%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $142.2M |
| 净利润 | $27.5M | $3.2M |
| 毛利率 | — | — |
| 营业利润率 | 14.1% | 2.3% |
| 净利率 | 11.1% | 2.3% |
| 营收同比 | 29.6% | -0.6% |
| 净利润同比 | 367.5% | -44.8% |
| 每股收益（稀释后） | $1.14 | $0.14 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPRNGR
| Q4 25 | $247.1M | $142.2M | ||
| Q3 25 | $227.8M | $128.9M | ||
| Q2 25 | $211.4M | $140.6M | ||
| Q1 25 | $197.1M | $135.2M | ||
| Q4 24 | $190.6M | $143.1M | ||
| Q3 24 | $148.3M | $153.0M | ||
| Q2 24 | $138.0M | $138.1M | ||
| Q1 24 | $137.4M | $136.9M |
净利润ANIPRNGR
| Q4 25 | $27.5M | $3.2M | ||
| Q3 25 | $26.6M | $1.2M | ||
| Q2 25 | $8.5M | $7.3M | ||
| Q1 25 | $15.7M | $600.0K | ||
| Q4 24 | $-10.3M | $5.8M | ||
| Q3 24 | $-24.2M | $8.7M | ||
| Q2 24 | $-2.3M | $4.7M | ||
| Q1 24 | $18.2M | $-800.0K |
营业利润率ANIPRNGR
| Q4 25 | 14.1% | 2.3% | ||
| Q3 25 | 15.9% | 2.0% | ||
| Q2 25 | 6.6% | 6.1% | ||
| Q1 25 | 13.3% | 0.7% | ||
| Q4 24 | -2.3% | 6.2% | ||
| Q3 24 | -13.8% | 8.4% | ||
| Q2 24 | 3.7% | 5.3% | ||
| Q1 24 | 14.8% | -0.4% |
净利率ANIPRNGR
| Q4 25 | 11.1% | 2.3% | ||
| Q3 25 | 11.7% | 0.9% | ||
| Q2 25 | 4.0% | 5.2% | ||
| Q1 25 | 8.0% | 0.4% | ||
| Q4 24 | -5.4% | 4.1% | ||
| Q3 24 | -16.3% | 5.7% | ||
| Q2 24 | -1.7% | 3.4% | ||
| Q1 24 | 13.2% | -0.6% |
每股收益（稀释后）ANIPRNGR
| Q4 25 | $1.14 | $0.14 | ||
| Q3 25 | $1.13 | $0.05 | ||
| Q2 25 | $0.36 | $0.32 | ||
| Q1 25 | $0.69 | $0.03 | ||
| Q4 24 | $-0.45 | $0.24 | ||
| Q3 24 | $-1.27 | $0.39 | ||
| Q2 24 | $-0.14 | $0.21 | ||
| Q1 24 | $0.82 | $-0.03 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $10.3M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $540.7M | $300.1M |
| 总资产 | $1.4B | $419.3M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ANIPRNGR
| Q4 25 | $285.6M | $10.3M | ||
| Q3 25 | $262.6M | $45.2M | ||
| Q2 25 | $217.8M | $48.9M | ||
| Q1 25 | $149.8M | $40.3M | ||
| Q4 24 | $144.9M | $40.9M | ||
| Q3 24 | $145.0M | $14.8M | ||
| Q2 24 | $240.1M | $8.7M | ||
| Q1 24 | $228.6M | $11.1M |
总债务ANIPRNGR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $0 | ||
| Q3 24 | — | $0 | ||
| Q2 24 | — | $0 | ||
| Q1 24 | — | $0 |
股东权益ANIPRNGR
| Q4 25 | $540.7M | $300.1M | ||
| Q3 25 | $505.8M | $270.0M | ||
| Q2 25 | $436.8M | $276.9M | ||
| Q1 25 | $418.6M | $272.6M | ||
| Q4 24 | $403.7M | $273.8M | ||
| Q3 24 | $405.9M | $267.6M | ||
| Q2 24 | $455.8M | $260.5M | ||
| Q1 24 | $452.0M | $261.7M |
总资产ANIPRNGR
| Q4 25 | $1.4B | $419.3M | ||
| Q3 25 | $1.4B | $372.8M | ||
| Q2 25 | $1.3B | $381.7M | ||
| Q1 25 | $1.3B | $376.5M | ||
| Q4 24 | $1.3B | $381.6M | ||
| Q3 24 | $1.3B | $373.9M | ||
| Q2 24 | $920.8M | $359.6M | ||
| Q1 24 | $914.5M | $355.5M |
负债/权益比ANIPRNGR
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 0.00× | ||
| Q3 24 | — | 0.00× | ||
| Q2 24 | — | 0.00× | ||
| Q1 24 | — | 0.00× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $24.1M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $17.1M |
| 自由现金流率自由现金流/营收 | 11.8% | 12.0% |
| 资本支出强度资本支出/营收 | 0.5% | 4.9% |
| 现金转化率经营现金流/净利润 | 1.10× | 7.53× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $42.9M |
8季度趋势，按日历期对齐
经营现金流ANIPRNGR
| Q4 25 | $30.4M | $24.1M | ||
| Q3 25 | $44.1M | $13.6M | ||
| Q2 25 | $75.8M | $20.7M | ||
| Q1 25 | $35.0M | $10.6M | ||
| Q4 24 | $15.9M | $32.7M | ||
| Q3 24 | $12.5M | $17.7M | ||
| Q2 24 | $17.4M | $22.1M | ||
| Q1 24 | $18.3M | $12.0M |
自由现金流ANIPRNGR
| Q4 25 | $29.1M | $17.1M | ||
| Q3 25 | $38.0M | $8.0M | ||
| Q2 25 | $71.8M | $14.4M | ||
| Q1 25 | $32.5M | $3.4M | ||
| Q4 24 | $13.5M | $27.3M | ||
| Q3 24 | $7.7M | $10.8M | ||
| Q2 24 | $13.0M | $6.8M | ||
| Q1 24 | $13.7M | $5.5M |
自由现金流率ANIPRNGR
| Q4 25 | 11.8% | 12.0% | ||
| Q3 25 | 16.7% | 6.2% | ||
| Q2 25 | 34.0% | 10.2% | ||
| Q1 25 | 16.5% | 2.5% | ||
| Q4 24 | 7.1% | 19.1% | ||
| Q3 24 | 5.2% | 7.1% | ||
| Q2 24 | 9.4% | 4.9% | ||
| Q1 24 | 10.0% | 4.0% |
资本支出强度ANIPRNGR
| Q4 25 | 0.5% | 4.9% | ||
| Q3 25 | 2.7% | 4.3% | ||
| Q2 25 | 1.9% | 4.5% | ||
| Q1 25 | 1.3% | 5.3% | ||
| Q4 24 | 1.3% | 3.8% | ||
| Q3 24 | 3.2% | 4.5% | ||
| Q2 24 | 3.2% | 11.1% | ||
| Q1 24 | 3.3% | 4.7% |
现金转化率ANIPRNGR
| Q4 25 | 1.10× | 7.53× | ||
| Q3 25 | 1.66× | 11.33× | ||
| Q2 25 | 8.87× | 2.84× | ||
| Q1 25 | 2.23× | 17.67× | ||
| Q4 24 | — | 5.64× | ||
| Q3 24 | — | 2.03× | ||
| Q2 24 | — | 4.70× | ||
| Q1 24 | 1.00× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RNGR
| High Specification Rigs | $92.3M | 65% |
| Processing Solutions And Ancillary Services | $37.5M | 26% |
| Wireline Services | $12.4M | 9% |
